A leading expert on ocular vascular disease and ocular drug delivery, Dr. Adamis is best known for his co-discovery of the role that vascular endothelial growth factor (VEGF) plays in neovascularization and vascular permeability related to various diseases of the eye. His findings sparked important research advances in the treatment of such conditions as macular degeneration and diabetic retinopathy and continue to shape the course of research in these areas today. Dr. Adamis has authored over 100 publications. Prior to joining Eyetech, Dr. Adamis was an Associate Professor of Ophthalmology at the Harvard Medical School and served as a Principal Investigator and Co-Director of the Retina Research Institute for Diabetic Retinopathy and Macular Degeneration at Massachusetts Eye and Ear Infirmary, a teaching affiliate of Harvard Medical School. Dr. Adamis' affiliation with these institutions dates back to 1989, when he began his clinical and research fellowships at the Massachusetts Eye and Ear Infirmary. Dr. Adamis also completed a vascular biology fellowship with Dr. Judah Folkman at the Children's Hospital of Boston and later served as a Principal Investigator in the Surgical Research Laboratory at Children's Hospital. He received his M.D. degree from the University of Chicago and completed his residency in ophthalmology at the University of Michigan.

Prior to joining Eyetech, Dr. Cunningham worked at Pfizer, Inc., where he was an Early Clinical Leader responsible for the development of lead central nervous system compounds, and for in-licensing early and late-stage central nervous system and ophthalmology therapeutic candidates. Dr. Cunningham is also an internationally recognized authority in the field of infectious and inflammatory eye disease, having written over 100 publications in the field. His current academic title is Research Professor of Ophthalmology at New York University School of Medicine. Dr. Cunningham completed medical school at the Johns Hopkins University, residency training in ophthalmology at UCSF, a fellowship in cornea, external disease and uveitis at the Francis I. Proctor Foundation, and a fellowship in public health ophthalmology at the Wilmer Eye Institute.

Ms. daSilva joined Hoffmann-La Roche in 1989 where she has held various positions in the regulatory affairs group. She has expertise in all areas of regulatory affairs, including being appointed as head of biologics. She has worked in a variety of therapeutic areas including oncology, virology, infectious diseases, gastroenterology, ophthalmology and radiopharmaceuticals. Ms. daSilva was the regulatory leader for Hoffman-La Roche's global alpha interferon studies in AMD. She has worked with both CDER and CBER at the FDA.

A veteran of several new drug approval campaigns, Ms. daSilva most recently completed Hoffman-La Roche's BLA filing for PEGASYS in the treatment of hepatitis C. She holds as B.S. in Microbiology from Pennsylvania State University and an M.S. in Regulatory Affairs from Long Island University.

Ms. Harrison was Director of Clinical Operations for Hoffmann-La Roche where she had global responsibility for the development and implementation of strategic plans for the clinical development programs for Roche's oncology franchise.

She has worked on all phases of global clinical trials and her extensive work in the fields of bone marrow transplantation, organ transplantation, oncology, virology and infectious diseases proved useful in obtaining several new drug approvals in the U.S. and Europe. She also led the Study Management Team for International multi-center Phase II and III Oncology clinical trials. Her efforts led to the approvals of Zenapax for treatment of acute organ rejection in renal transplantation and Xeloda for treatment of breast and colon cancers.

Prior to joining Hoffmann-La Roche, Ms. Harrison worked at Cornell University Medical College as a research assistant in the infectious disease department. She holds an M.B.A. from Manhattan College and a BA in Biology from Hofstra University.

Prior to EyeTech Pharmaceuticals, Mr. Kollmorgen was a Senior Director of Quality Assurance with Knoll Pharmaceutical Company. With over 22 years of comprehensive chemical and pharmaceutical manufacturing, quality and regulatory experience, Mr. Kollmorgen has significant expertise in the areas of Analytical Chemistry, Quality Assurance / Control, Regulatory Affairs and Technical Management. He holds a B.S. in Biology from Bowling Green State University and an M.B.A. from Lake Erie College.

From 1994 to 2000, Mr. O'Connor held various positions at Allelix Neurosciences, Inc. (formerly Trophix Pharmaceuticals, Inc.), most recently serving as Vice President Finance. Prior to April 1994, Mr. O'Connor was with the firm of Richard A. Eisner and Company, LLP, Certified Public Accountants, most recently serving as Audit Partner, specializing in venture-financed, technology start-up companies.

Mr. O'Connor holds a B.S. in Accounting from the Fairleigh Dickinson University and is a Certified Public Accountant.

Dr. O'Shaughnessy is a senior pharmaceutical executive with over twenty years of international pharmaceutical experience and expertise in clinical development.

He and his team at Hoffmann-La Roche were responsible for the clinical trials leading to the approval of over 20 pharmaceutical products/indications. Prior to joining Eyetech, Dr. O'Shaughnessy was a senior manager responsible for overseeing global clinical research programs at Hoffmann-La Roche. While there, he ran its pivotal Phase III drug study, testing Roferon for the treatment of AMD, gaining valuable experience in dealing with the clinical sites and the FDA in designing and running clinical trials of the type being used for the aptamer.

He obtained his Ph.D. from Royal Post-Graduate Medical School in the United Kingdom and his undergraduate degree from London University.

Mr. Sblendorio was the former Senior Vice President - Business Development for The Medicines Company, a specialty pharmaceuticals company. Prior to that, he was Chief Executive Officer and Managing Director at MPM Capital Advisors. He has also served as Senior Vice-President and CFO at Sony Interactive Entertainment where he was part of the senior management team responsible for, among other things, the Sony Playstation. Mr. Sblendorio’s extensive pharmaceuticals experience also includes 12 years at Hoffmann-La Roche in a variety of senior financial positions, including CFO of Roche Molecular Systems and Head of Finance-Controller for Amgen/Roche Europe. He is a certified public accountant and also holds a BBA in Accounting from Pace University and an M.B.A. in Finance from Fairleigh Dickinson University.

Dr. Scypinski received his B.S., M.S. and Ph.D. degrees in Chemistry from Seton Hall University. Involved in analytical and pharmaceutical chemistry for over 22 years, Dr. Scypinski has held positions at Exxon Research and Engineering Co., Varian Instrument Group, Berlex Laboratories and Hoffmann-La Roche. His most recent position prior to joining Eyetech was Director of the Analytical Chemistry Research & Development Department at The R.W. Johnson Pharmaceutical Research Institute. An accomplished scientist as well as manager, Dr. Scypinski serves on the editorial review board for several analytical chemistry journals and is co-editor of the textbook “Handbook of Pharmaceutical Analysis.” Well-versed in both the scientific and regulatory facets of pharmaceutical analysis, Dr. Scypinski has experience both in US and worldwide regulatory filings as well as the pre-approval inspection process.

A leading researcher in angiogenesis and vascular cell biology, Dr. Shima worked with Dr. Adamis and collaborators during the early 1990’s on pioneering studies that elucidated the role of Vascular Endothelial Growth Factor (VEGF) during pathological neovascularization within the eye. Dr. Shima’s subsequent research efforts have expanded upon these early findings, yielding important mechanistic insight into how VEGF orchestrates the multi-step process of new blood vessel formation. His investigations of intercellular communication within the cardiovasculature have also resulted in the identification and characterization of novel components of the angiogenic machinery, which represent potential targets for clinical intervention aimed at the treatment of ocular vascular disease. Prior to joining Eyetech in the latter part of 2002, Dr. Shima was the head of the Endothelial Cell Biology Laboratory at the Imperial Cancer Research Fund in London, England, where he also completed his post-doctoral training in membrane biology and biochemistry. Dr. Shima received his PhD in 1995 from the Program in Cell and Developmental Biology, Harvard University.

During a pharmaceutical career stretching over ten years and numerous therapeutic areas, Mr. Ural has spearheaded marketing, sales and business development initiatives in the United States and overseas. Mr. Ural's experience in launching products worldwide including the launch of Viagra® will play an important role for Eyetech's commercialization of Macugen TM to meet an unmet medical need.

Most recently, Mr. Ural was Pfizer’s Team Leader for Celebrex in the United States, and was responsible for worldwide consumer promotion efforts for both Celebrex® and Bextra®, Pfizer’s recently launched COX-2 inhibitor.

Mr. Ural has BSc and MSc degrees in Mechanical Engineering from Bosporus University in Istanbul, Turkey where he had taught material science prior to joining Pfizer in 1992. He also has an MBA degree from Marmara University in Istanbul, and completed Harvard Business School’s Executive Development Program.

Dr. Wincott joined Eyetech in April 2002 after nine years at Ribozyme Pharmaceuticals, Inc. (Boulder, Colorado) where she most recently served as Senior Director, Manufacturing Operations. While at Ribozyme, Dr. Wincott led teams that developed proprietary manufacturing methods, significantly increased the yield and scale of, and reduced production costs, for Ribozyme's compounds. Dr. Wincott holds a B.A. in Chemistry from the University of Pennsylvania and a Ph.D. in Organic Chemistry from Yale University. She has authored 20 publications and holds 11 patents in the oligonucleotide field.